Mechanism of Aspirin in Colorectal Cancer Prevention
Aspirin prevents colorectal cancer through multiple interconnected mechanisms, primarily by irreversibly inhibiting COX-1 and COX-2 enzymes, which blocks prostaglandin E2 (PGE2) synthesis and subsequently disrupts WNT-β-catenin signaling, platelet activation, and inflammatory pathways that drive tumorigenesis. 1
Primary Mechanism: COX Inhibition and Prostaglandin Suppression
The central mechanism involves aspirin's irreversible acetylation of prostaglandin-endoperoxide synthase enzymes (PTGS1/COX-1 and PTGS2/COX-2), which prevents conversion of arachidonic acid to downstream prostaglandins 2. This is fundamentally different from other NSAIDs that reversibly inhibit these enzymes.
The COX-2/PGE2 pathway is particularly critical because:
- PGE2 synthesis is consistently elevated in colorectal neoplasia 1
- Genetic deletion of Ptgs2 or PGE2 receptor genes reduces intestinal tumor burden in mouse models 1
- Aspirin use reduces risk specifically in tumors that overexpress COX-2 (RR = 0.64; 95% CI 0.52–0.78), but shows no benefit in COX-2-negative tumors (RR = 0.96; 95% CI 0.73–1.26) 1
The HPGD "Brake" System
15-hydroxyprostaglandin dehydrogenase (HPGD) acts as a metabolic antagonist to COX-2 by catabolizing PGE2 to its inactive metabolite PGE-M 1. Aspirin's effectiveness is enhanced when HPGD expression is high:
- Aspirin reduced CRC risk by 51% (HR = 0.49; 95% CI 0.34–0.71) in individuals with high colonic HPGD expression 1
- No protection was observed in those with low HPGD expression (Pheterogeneity = 0.02) 1
This explains why aspirin doesn't work uniformly—the tissue must have adequate "braking" capacity to amplify aspirin's prostaglandin-blocking effects.
Secondary Mechanism: WNT-β-Catenin Pathway Inhibition
Aspirin disrupts oncogenic WNT signaling through two routes 1, 3:
Indirect suppression via PGE2 reduction: PGE2 activates WNT-β-catenin signaling through paracrine activation of the EP2 receptor and cAMP/PKA pathways, which stabilize cytosolic β-catenin 1
Direct inactivation of protein phosphatase 2A (PP2A): This prevents removal of post-translational modifications that normally target β-catenin for destruction 1
Recent proteomic data confirm that aspirin downregulates WNT6 production by suppressing its transcription factor NR4A2, which is itself regulated by PGE2 3. This creates a reinforcing loop where prostaglandin suppression cascades into reduced oncogenic signaling.
Tertiary Mechanisms: Antiplatelet and Anti-Inflammatory Effects
Low-dose aspirin's antiplatelet effects contribute to cancer prevention through COX-1 inhibition, which blocks thromboxane A2 (TXA2) production and prevents platelet recruitment 1. Platelets and infiltrating inflammatory cells (neutrophils, fibroblasts) act as paracrine activators of epithelial COX-2 during chronic inflammation 1.
The combined antiplatelet and anti-inflammatory effects appear particularly effective in inflammation-associated tumorigenesis:
- Aspirin reduced tumor necrosis factor alpha and reactive oxygen species in mouse models 4
- Suppression of COX-2, iNOS, and YAP1 (Yes-associated protein 1) at tumor sites 4
- Decreased 8-nitroguanine, a marker of inflammation-related DNA damage 4
COX-Independent Mechanisms
While less dominant, aspirin exerts additional anticancer effects independent of COX inhibition 5:
- Down-regulation of nuclear factor kappa B (NF-κB) activity
- Modulation of apoptotic proteins (Bcl-2 and Bax families)
- Suppression of vascular endothelial growth factor (VEGF)
- Disruption of DNA repair mechanisms
- Induction of p53 and cell cycle arrest via p53-CDK1 pathway 6
Recent proteomic analysis showed aspirin upregulated p53 by 2.52-fold and downregulated CDK1 to half of control levels, promoting G1/S cell cycle arrest and apoptosis in colon cancer cells 6.
Immune Microenvironment Modulation
Emerging evidence shows aspirin regulates the tumor immune microenvironment 7:
- Reduces abundance of pro-tumorigenic bacteria (Enterococcus cecorum)
- Increases CD155+ tumor cells and TIGIT expression on CD4+CD25+ Treg cells
- Elevated TIGIT reduces Treg functionality, which correlates with enhanced CD8+ T cells, Th2 cells, and Th17 cells 7
This suggests aspirin's mechanism extends beyond direct tumor cell effects to include microbiome and immune checkpoint modulation.
Molecular Subtype Specificity
Critical caveat: Aspirin's benefit is restricted to specific molecular subtypes 1:
- Effective in BRAF-wild-type CRC (HR = 0.73; 95% CI 0.64–0.83)
- No benefit in BRAF-mutant CRC (HR = 1.03; 95% CI 0.76–1.38; Pheterogeneity = 0.005)
- Most effective in tumors that are both COX-2-overexpressing AND BRAF-wild-type 1
BRAF-mutant cancers likely emerge through the serrated pathway with upregulated MAPK signaling, making them less dependent on prostaglandin-mediated pathways 1.
Clinical Translation: The PI3K Connection
The most recent and highest-quality evidence demonstrates that PI3K pathway alterations predict aspirin benefit 8. In the 2025 ALASCCA trial, aspirin reduced 3-year recurrence from 14.1% to 7.7% (HR 0.49; 95% CI 0.24–0.98) in patients with PIK3CA hotspot mutations 8. This validates the mechanistic link between prostaglandin signaling, PI3K pathway activation, and aspirin's anticancer effects.
The mechanism converges here: PGE2 activates PI3K/AKT signaling, and tumors with PI3K pathway alterations are particularly dependent on this prostaglandin-driven proliferation signal that aspirin blocks 1.